HF/Arrhytmias trials 761

Question 1

SOLVD

Answer 1

Looked at ACEi (Enalapril) in comparison to Vasodilator Heart failure trial (V-Heft)

Question 2

CHARM

Answer 2

Looked at ARB (Candesartan) in increasing primary outcome of reduced CV death

Question 3

PARADIGM

Answer 3

Looked at ARNI, first time to give class 1A recommendation off a single trial

Question 4

SHIfT

Answer 4

Looked at giving Ivabridine in HFrEF <35%, not to be given in A-fib

Question 5

RALES/EPHESUS/EMPHASIS

Answer 5

Looked at Aldosterone Antagonists in reducing mortality

Question 6

A-HEFT

Answer 6

Looked at Hydralazine and Isosorbide Dinitrate and reducing mortality in black populations

Question 7

DIG/DIG II

Answer 7

Looked at Digoxin and its hospitalization benefits but showed no increase in mortality

Question 8

DOSE

Answer 8

Looked at diuretics and increased dose for improving dyspnea symptoms. Bolus vs Continuous Infusion did not matter

Question 9

OPTIME-CHF

Answer 9

Milrinone use did not decrease hospitilizations or CV events, with increase in Side effects

Question 10

ADHERE

Answer 10

Ionotropes had increased mortality over vasodilators

Question 11

ASCEND

Answer 11

HF –> Nesiritide did not perform better than placebo in death or hospitilization

Question 12

REMATCH/HEARTMATE

Answer 12

continuous flow in left ventricular assistance devices was best way to reduce mortality. Rate can be sped or slowed to help GI bleeds

Question 13

CAPRIE

Answer 13

Clopidogrel vs ASA, tie for post MI and PAD. Plavix slightly better.

Question 14

CURE

Answer 14

ASA + Plavix > ASA + Placebo

in the treatment of Unstable Angina

Question 15

CHARISMA

Answer 15

ASA + Placebo > ASA + Plavix

In treatment of stable disease

Question 16

PRAGUE

Answer 16

Second agent for DAPT literally doesn’t matter, trial stopped for futility

Question 17

CAST

Answer 17

Looked at suppressing PVCs post MI for preventing Sudden Cardiac Death, no benefit. Flecainide, Encainide and Merizicine all had increased mortality. Do not use in Structural Heart Disease

Question 18

SWORD

Answer 18

Sotalol in treatment of post MI w/ HFrEF was worse than placebo

Question 19

MADIT-II

Answer 19

Post-MI with EF <30. use of Implantable Cardiac Defibrilators increased survivability vs conventional therapy.

Question 20

SCD-HEFT

Answer 20

Amiodarone increased mortality

ICDs decrease mortality w/ non-ischemic CHF

Question 21

AFFIRM

Answer 21

Looked at A-fib and Rate vs Rhythm. No mortality benefit with rhythm control. Importance of continued use of anticoag therapy in patients with strokes.

Question 22

RACE

Answer 22

Looked at strict vs lenient rate control, no benefit, but did not look into QOL

Question 23

ATHENA

Answer 23

Looked at Dronendarone vs Placebo, saw reduction in hospitalizations.

Question 24

ANDROMEDA

Answer 24

Looked at Dronendarone vs Placebo, saw increase in mortality in patients with HFrEF <30%

Question 25

PALLAS

Answer 25

Looked at Dronendarone vs Placebo in patients with permanent A-Fib. DO NOT do